SynBiotic SE (FRA:SBX)

Germany flag Germany · Delayed Price · Currency is EUR
3.080
+0.010 (0.33%)
At close: Jul 18, 2025, 10:00 PM CET
-60.61%
Market Cap24.48M
Revenue (ttm)3.86M
Net Income (ttm)-10.63M
Shares Outn/a
EPS (ttm)-2.24
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume2,300
Average Volume3,437
Open3.025
Previous Close3.070
Day's Range3.025 - 3.080
52-Week Range2.550 - 8.720
Betan/a
RSI45.20
Earnings DateAug 15, 2025

About SynBiotic SE

SynBiotic SE engages in the research and development, production, and marketing of cannabinoid and terpene-based solutions to for pain, sleep deprivation, and anxiety. It also offers hemp, cannabinoids, dietary supplements, and cosmetic products; medical cannabis products; and cannabis products for recreational use under the Hempamed, Princess Stardust, The Hempany, and Hempamed Rx brand names. The company was formerly known as Ledgertech SE and changed its name to SynBiotic SE. SynBiotic SE was founded in 2017 and is based in Munich, Germany. [Read more]

Industry Pharmaceutical Preparations
Founded 2017
Employees 55
Stock Exchange Frankfurt Stock Exchange
Ticker Symbol SBX
Full Company Profile

Financial Performance

In 2023, SynBiotic SE's revenue was 3.86 million, a decrease of -52.71% compared to the previous year's 8.17 million. Losses were -10.63 million, -56.36% less than in 2022.

Financial Statements

News

EQS-DD: SYNBIOTIC SE: HempConsult GmbH, Lending (free of charge) of 50,000 shares as part of a securities lending programme.

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them 23.04.2025 / 09:22 CET/CEST The issuer is solely responsi...

3 months ago - Wallstreet:Online